Summary (tl;dr)

Moderna's stock is experiencing significant volatility, plummeting by about 25% today, October 22, 2026, after highly anticipated Phase 3 clinical trial data for its personalized melanoma cancer vaccine, intismeran autogene, was reportedly leaked online ahead of its official presentation. This dramatic drop follows a period of substantial gains for the company, largely driven by earlier positive topline results for the same vaccine.

Essential Background

Moderna, a biotechnology company, became a household name during the COVID-19 pandemic for its mRNA vaccine. Following the pandemic, the company faced challenges with plummeting demand for its COVID-19 vaccine and underperforming additional projects, leading to revised financial projections and strategic shifts. However, Moderna's stock began a significant turnaround in 2026, with shares climbing over 600% this year. This surge was largely fueled by the August 2026 announcement of positive topline results from the Phase 3 INTerpath-001 trial for intismeran autogene, its personalized cancer vaccine for high-risk melanoma, co-developed with Merck & Co. While the August announcement indicated the trial met its primary and secondary endpoints, specific detailed data was not released at the time.

The Full Story

Today, October 22, 2026, Moderna's stock (MRNA) plunged approximately 24-25% following a reported premature release of the full Phase 3 data for its melanoma vaccine, intismeran autogene, developed in partnership with Merck. The data, which was scheduled to be officially presented at the European Society for Medical Oncology (ESMO) Congress in Madrid on October 24, was briefly published by a cancer news website, Oncology Central, before being removed.

The leaked data indicated that intismeran autogene combined with Merck's Keytruda (pembrolizumab) reduced the risk of melanoma recurrence or death by 42% compared to Keytruda alone. At two years, 82.2% of patients on the combination therapy were alive, versus 70% for those on Keytruda monotherapy. Despite these seemingly positive results, the market reacted negatively, leading to a significant sell-off and erasing nearly $20 billion from Moderna's market value.

Why It Matters

The leak and subsequent stock plunge highlight the extreme sensitivity of investor sentiment to clinical trial data, especially for high-profile biotechnology companies. While the leaked data shows promising efficacy for the personalized cancer vaccine, indicating a significant advancement in melanoma treatment, the negative market reaction suggests investors may have already priced in more optimistic outcomes or are reacting to the uncertainty caused by the premature release. This event could influence future stock performance for Moderna and other biotech companies, particularly concerning how crucial data is managed and released to avoid similar market volatility. For cancer patients, the successful trial results represent a potential groundbreaking new approach to treating melanoma, utilizing a patient's own DNA for a custom treatment.

Geographic Location

• Cambridge, Middlesex County, Massachusetts, United States (Moderna's headquarters)
• Madrid, Community of Madrid, Spain (Location of the European Society for Medical Oncology Congress where full Phase 3 data was scheduled for release)